

Jeffrey M. Zirger,

Lead, Information Collection Review Office,  
Office of Public Health Ethics and  
Regulations, Office of Science, Centers for  
Disease Control and Prevention.

[FR Doc. 2024-05775 Filed 3-18-24; 8:45 am]

BILLING CODE 4163-18-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Notice of Award of a Sole Source Cooperative Agreement To Fund Ministry of Health of Mozambique (MISAU)

**AGENCY:** Centers for Disease Control and  
Prevention (CDC), Department of Health  
and Human Services (HHS).

**ACTION:** Notice.

**SUMMARY:** The Centers for Disease  
Control and Prevention (CDC), located  
within the Department of Health and  
Human Services (HHS), announces the  
award(s) of approximately \$10,000,000,  
for Year 1 funding to MISAU. The(se)  
award(s) will support the GRM through  
MISAU to continue to address  
Tuberculosis (TB) and human  
immunodeficiency virus (HIV) as a  
public health problem through the  
expansion of access to quality HIV  
prevention, care, and treatment services  
to reduce remaining gaps among  
children, adolescents, key populations  
(KP) and men. Funding amounts for  
years 2–5 will be set at continuation.

**DATES:** The period for this award will be  
September 30, 2024, through September  
29, 2029.

**FOR FURTHER INFORMATION CONTACT:**  
Scott Salo, Center for Global Health,  
Centers for Disease Control and  
Prevention, Avenida Marginal nr 5467  
Sommerschield, Distrito Municipal de  
KaMpfumo Caixa Postal 783 CEP 0101-  
11 Maputo, Moçambique, Telephone:  
404.553.7439, E-Mail: [evf1@cdc.gov](mailto:evf1@cdc.gov).

**SUPPLEMENTARY INFORMATION:** The sole  
source award(s) will strengthen  
technical, managerial, and institutional  
capacities at MISAU to optimize some  
of the following approaches: youth  
appropriate HIV testing services, HIV-  
related DREAMS services for  
Adolescent Girls and Young Women,  
pre-exposure prophylaxis services,  
voluntary medical male circumcision  
services, cervical cancer services, and  
gender-based violence services. Other  
approaches include maternal and child  
health services, differentiated HIV  
service delivery models, and HIV and  
TB services.

MISAU is in a unique position to  
conduct this work, as it is the central  
institution of public sector, which  
according to the law of the Republic of  
Mozambique, is responsible for the  
implementation of health policy in the  
public, private, and community  
domains. MISAU, by law, has the  
authority to lead, provide oversight,  
monitor the implementation of  
healthcare programs and services at  
national level, and is mandated to  
develop policies and guidelines, and  
plan, manage, and coordinate all health-  
related activities including HIV/TB  
services.

#### Summary of the Award

*Recipient:* Ministry of Health of  
Mozambique (MISAU).

*Purpose of the Award:* The purpose of  
this award is to to prepare MISAU to  
sustain the gains of the national HIV  
response through the development of a  
measurable roadmap for sustainability  
and support the Government of  
Mozambique through MISAU to  
continue to address HIV/TB as a public  
health problem through the expansion  
of access to quality HIV prevention,  
care, and treatment services to reduce  
remaining gaps among children,  
adolescents, KP, and men.

*Amount of Award:* For MISAU, the  
approximate year 1 funding amount will  
be \$10,000,000 in Federal Fiscal Year  
(FFY) 2024 funds, subject to the  
availability of funds. Funding amounts  
for years 2–5 will be set at continuation.

*Authority:* This program is authorized  
under Public Law 108–25 (the United  
States Leadership Against HIV AIDS,  
Tuberculosis and Malaria Act of 2003)  
[22 U.S.C. 7601, *et seq.*] and Public Law  
110–293 (the Tom Lantos and Henry J.  
Hyde United States Global Leadership  
Against HIV/AIDS, Tuberculosis, and  
Malaria Reauthorization Act of 2008),  
and Public Law 113–56 (PEPFAR  
Stewardship and Oversight Act of 2013).

*Period of Performance:* The period for  
this award will be September 30, 2024,  
through September 29, 2029.

Dated: March 13, 2024.

**Jamie Legier,**

Acting Director, Office of Grants Services,  
Centers for Disease Control and Prevention.

[FR Doc. 2024-05778 Filed 3-18-24; 8:45 am]

BILLING CODE 4163-18-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Notice of Award of a Sole Source Cooperative Agreement To Fund International Union Against Tuberculosis and Lung Disease (The Union)

**AGENCY:** Centers for Disease Control and  
Prevention (CDC), Department of Health  
and Human Services (HHS).

**ACTION:** Notice.

**SUMMARY:** The Centers for Disease  
Control and Prevention (CDC), located  
within the Department of Health and  
Human Services (HHS), announces the  
award of approximately \$500,000, for  
Year 1 funding to The Union. The award  
will continue developing and updating  
Tuberculosis (TB) scientific and  
programmatic resources, disseminating  
TB best practices, and building TB  
capacity. Funding amounts for years 2–  
5 will be set at continuation.

**DATES:** The period for this award will be  
September 30, 2024, through September  
29, 2029.

**FOR FURTHER INFORMATION CONTACT:**  
Victoria Tully, Center for Global Health,  
Centers for Disease Control and  
Prevention, 1600 Clifton Road, MS  
US1-1 Atlanta, Georgia 30329,  
Telephone: 404.718.2549, E-Mail: [nts2@cdc.gov](mailto:nts2@cdc.gov).

**SUPPLEMENTARY INFORMATION:** The sole  
source award will focus on developing  
and updating scientific and  
programmatic resources, disseminating  
clinical and programmatic best  
practices, and building capacity. These  
activities are expected to equip health  
officials, health professionals, and  
health care and public health workers  
with skills and knowledge based on the  
latest TB recommendations.

The Union is in a unique position to  
conduct this work, as it was given the  
mandate: (1) to establish a Federation  
amongst the national associations or  
organizations engaged in the campaign  
against TB, to coordinate their efforts  
throughout the world, and to work in  
collaboration with international  
organizations to end TB disease; (2) to  
organize scientific conferences and  
congresses regarding TB; (3) to compare  
national legislation in preventing and  
controlling TB; (4) to collect  
international TB statistics; (5) to  
stimulate scientific and social  
investigations regarding the  
distribution, spread, prevention, and  
treatment of TB in various countries;  
and (6) to collect and distribute

information to national organizations included in The Union on all questions concerning scientific and sociological study on TB. The Union is uniquely qualified to combat TB and lung disease globally and to offer training and other capacity-building activities leading to health solutions for the poor in resource limited countries, the key activities under this NOFO, due to its WHO-recognized accomplishments and leadership role in the global TB fight since its founding in 1920.

### Summary of the Award

*Recipient:* International Union Against Tuberculosis and Lung Disease (The Union).

*Purpose of the Award:* The purpose of this award is to continue developing and updating TB scientific and programmatic resources, disseminating TB best practices, and building TB capacity.

*Amount of Award:* For The Union, the approximate year 1 funding amount will be \$500,000 in Federal Fiscal Year (FYY) 2024 funds, subject to the availability of funds. Funding amounts for years 2–5 will be set at continuation.

*Non-PEPFAR Authority:* This program is authorized under section 307 of the Public Health Service Act (42 U.S.C. 242l), as amended and section 301(a) of the Public Health Service Act (42 U.S.C. 241(a)), as amended.

*Period of Performance:* The period for this award will be September 30, 2024, through September 29, 2029.

Dated: March 13, 2024.

**Jamie Legier,**

*Acting Director, Office of Grants Services,  
Centers for Disease Control and Prevention.*

[FR Doc. 2024–05771 Filed 3–18–24; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA–2024–N–1181]

#### **Air Products and Chemicals, Inc.; Withdrawal of Approval of a New Drug Application and New Animal Drug Application for Helium, USP**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA or Agency) is withdrawing approval of the new drug application (NDA) 205864 and the new animal drug application (NADA) 141–395 for the designated medical gas Helium, USP held by Air Products and

Chemicals, Inc., 1940 Air Products Blvd., Allentown, PA 18106–5500 (Air Products). Air Products notified the Agency in writing that the drug product was no longer marketed and requested that the approval of the application be withdrawn.

**DATES:** Approval is withdrawn as of April 18, 2024.

**FOR FURTHER INFORMATION CONTACT:** Kimberly Lehrfeld, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6226, Silver Spring, MD 20993–0002, 301–796–3137, [Kimberly.Lehrfeld@fda.hhs.gov](mailto:Kimberly.Lehrfeld@fda.hhs.gov); or Scott Fontana (HFV–180), Center for Veterinary Medicine, Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240–402–0656, [Scott.Fontana@fda.hhs.gov](mailto:Scott.Fontana@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:** Air Products has informed FDA that it is no longer marketing the designated medical gas Helium, USP and has requested that FDA withdraw approval of NDA 205864 and NADA 141–395 under the processes in § 314.150© (21 CFR 314.150(c)) and § 514.115(d) (21 CFR 514.115(d)). Air Products has also, by its request, waived its opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) or an NADA or abbreviated new animal drug application under § 514.115(d) is without prejudice to refiling.

Therefore, approval of NDA 205864 and NADA 141–395, and all amendments and supplements thereto, are hereby withdrawn as of April 18, 2024. Introduction or delivery for introduction into interstate commerce of Helium, USP, without an approved new drug application or an approved new animal drug application violates sections 505(a), 512(a), 301(a), and 301(d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(a), 360b(a)(1), 331(a), and 331(d)). Any Helium, USP manufactured by Air Products pursuant to these applications that is in inventory on April 18, 2024 may continue to be dispensed until the inventories have been depleted or the drug product has reached its expiration date or otherwise become violative, whichever occurs first.

Dated: March 13, 2024.

**Lauren K. Roth,**

*Associate Commissioner for Policy.*

[FR Doc. 2024–05742 Filed 3–18–24; 8:45 am]

**BILLING CODE 4164–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Committee on Vital and Health Statistics

**AGENCY:** Centers for Disease Control and Prevention, Department of Health and Human Services.

**ACTION:** Notice of meeting.

**SUMMARY:** Pursuant to the Federal Advisory Committee Act, the Department of Health and Human Services (HHS) announces the following advisory committee meeting. This meeting is open to the public. The public is welcome to attend in person or to obtain the link to attend this meeting by following the instructions posted on the Committee website: <https://ncvhs.hhs.gov/meetings/full-committee-meeting-16/>.

*Name:* National Committee on Vital and Health Statistics (NCVHS) Meeting.

**DATES:** Thursday, April 11, 2024: 9:15 a.m.–5:30 p.m. EDT and Friday, April 12, 2024: 8:30 a.m.–3:00 p.m. EDT.

**ADDRESSES:** In-person/hybrid (includes virtual attendance option).

**FOR MORE INFORMATION CONTACT:**

Substantive program information may be obtained from Rebecca Hines, MHS, Executive Secretary, NCVHS, National Center for Health Statistics, Centers for Disease Control and Prevention, 3311 Toledo Road, Hyattsville, Maryland 20782, or via electronic mail to [vgh4@cdc.gov](mailto:vgh4@cdc.gov); or by telephone (301) 458–4715. Summaries of meetings and a roster of Committee members are available on the NCVHS website <https://ncvhs.hhs.gov/>, where further information including an agenda and instructions to access the broadcast of the meeting will be posted.

Should you require reasonable accommodation, please telephone the CDC Office of Equal Employment Opportunity at (770) 488–3210 as soon as possible.

**SUPPLEMENTARY INFORMATION:**

*Purpose:* As outlined in its Charter, the National Committee on Vital and Health Statistics assists and advises the Secretary of HHS on health data, data standards, statistics, privacy, national health information policy, and the Department's strategy to best address those issues. Under the Health Insurance Portability and Accountability Act of 1996 (HIPAA),<sup>1</sup> NCVHS advises the Secretary on administrative simplification standards, including those for privacy, security,

<sup>1</sup>Public Law 104–191, 110 Stat. 1936 (Aug 21, 1996), available at <https://www.congress.gov/104/plaws/publ191/PLAW-104publ191.pdf>.